Guest column: Never safe to ignore depression

Guest column: Never safe to ignore depression
He was such an incredibly talented, caring and generous artist with a successful career and he supported many causes to help people (i.e. the homeless and veterans). We grieve and wonder what kind of depression could have been so dark and overwhelming …
Read more on CapitalGazette.com

Speaking out against the stigma of schizophrenia
“There's a huge stigma attached to mental illness and particularly the more serious mental illnesses like schizophrenia and bipolar disorder,” she said. “Stigma, generally speaking, is the number one reason why people don't go and get help and seek …
Read more on Cambridge Times

Falling for the whiteness of the Zionist narrative
In a bipolar world, there existed a duality of the superpowers as opposing forces and a recognition of the freedom fighter in postcolonial societies by either the American or the Soviet bloc depending on who opposed whom, but this category as a genuine …
Read more on Middle East Monitor

Happening Aug. 14
Men With Cancer Support Group, 7:30 a.m. Peitz Cancer Support House, 624 Hospital Drive. Includes breakfast. Facilitator: Dr. Bob Cogburn. TOPS AR 318, 8 a.m. First Baptist Church upper Fireside Room. North Arkansas Woodcarvers Club, 8:30 a.m. 214 …
Read more on Baxter Bulletin

Comments Off

Filed under Bipolar Support

Los Angeles Depression Treatment from Bridges to Recovery

Los Angeles, CA (PRWEB) July 29, 2014

Bridges to Recovery, the leaders in residential treatment for depression in Los Angeles, is honored to announce their new depression treatment programs that combine the latest in depression treatment research with a comfortable residential environment that is a healthy and effective alternative to traditional hospitals.

Bridges to Recovery has three locations in California to assist patients in dealing with depression or any other mental health matters, including PTSD, OCD, and Bipolar disorder.

Bridges to Recovery is celebrating 10 years of quality care for those who require assistance in handling disruptive and distressing emotional and mental health issues. Patients who are suffering with PTSD will find the help they need. Treatment may include: nutritional counseling, art therapy, yoga, massage therapy, meditation, weight training and aerobics under supervision, and dialectical behavioral therapy.

By checking in to a Bridges to Recovery facility, Major Depression patients can receive the medical and emotional help they need while living in a home-like, comfortable environment. The facilities do not have an institutional feel, so Major Depression patients will not feel as if they are institutionalized. The medical professionals of Bridges to Recovery understand that Major Depression can be a lifelong struggle and will thus make a recovery plan with each patient before they go back out into the world. Nearly 80% of all people who receive treatment for Major Depression recover, and seeking help from Bridges to Recovery is a positive step that can lead towards patients joining that number.

To receive more information on Bridges to Recoverys groundbreaking treatment plans and to get started on a new life, please visit the companys website at http://www.bridgestorecovery.com or contact Bridges to Recovery directly at 1-877-386-3398.







Comments Off

Filed under Bipolar Depression

Healthy Living Institute – What Is Bipolar Disorder?


Healthy Living Institute – What Is Bipolar Disorder?

from Living With Bipolar Disorder and Manic Depression

Price: USD 0.99
View Details about Healthy Living Institute

Comments Off

Filed under Bipolar Depression

Risperdal Breast-Growth Lawyer Help: Resource4thePeople Encouraged by Consumer Response to No-Cost Reviews of Breast-Growth Claims

San Diego, CA (PRWEB) April 24, 2014

http://www.resource4thepeople.com/defectivedrugs/risperdal.html

Resource4thePeople announced today that it is encouraged by the overwhelming response to its offer of free consultations to consumers over allegations that the antipsychotic medication Risperdal may cause a breast-growth condition known as gynecomastia or other side effects.

As a result of a larger-than-expected number of inquiries these consultations from its national network of attorneys will continue to be offered on a permanent basis in the future, said Resource4thePeople.

It is obvious that there are far more consumers who have been affected by the allegations* admitted to by the manufacturers of this medication in their guilty plea to charges filed by the U.S. Justice Department than first anticipated, said Resource4thePeople.

Therefore, we have decided to continue to offer these free consultations for any boy or man who has been affected by off-label or other uses of Risperdal in which gynecomastia or other serious side effects have occurred.

These non-approved uses of Risperdal were recently outlined* by the U.S. Justice Department and the Food and Drug Administration in the resolution of charges involving multimillion dollar criminal and civil penalties.

The Justice Department and FDA issued a joint Nov. 4, 2013 press release* in which they explained the resolution of charges against pharmaceutical giant Johnson & Johnson and its subsidiaries:

Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $ 2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nations largest long-term care pharmacy provider. The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $ 485 million and civil settlements with the federal government and states totaling $ 1.72 billion.

The conduct at issue in this case jeopardized the health and safety of patients and damaged the public trust, said Attorney General Eric Holder. This multibillion-dollar resolution demonstrates the Justice Departments firm commitment to preventing and combating all forms of health care fraud. And it proves our determination to hold accountable any corporation that breaks the law and enriches its bottom line at the expense of the American people.

The resolution includes criminal fines and forfeiture for violations of the law and civil settlements based on the False Claims Act arising out of multiple investigations of the company and its subsidiaries.

Resource4thePeople said its attorneys are investigating cases in which off-label uses of Risperdal resulted in a diagnosis of diabetes or tardive dyskinesia and gynecomastia (male breast development).

The Food and Drug Administration originally approved Risperdal in 1993 for the treatment of schizophrenia, although that approval later was expanded to also address bi-polar disorder.

Risperdal works by blocking dopamine, which releases prolactin from the pituitary gland. Thus, Risperdal creates a sedating effect on the patient, typical in antipsychotics of its class. It can be administered orally in the form of tablets or via a bi-weekly injection.

The Justice Department said that from March 3, 2002, through Dec. 31, 2003, Janssen Pharmaceuticals Inc., a J&J subsidiary, introduced the antipsychotic drug Risperdal into interstate commerce for an unapproved use, rendering the product misbranded.

For most of this time period, Risperdal was approved only to treat schizophrenia, the Justice Department said.

Justice officials said that Janssens sales representatives promoted Risperdal to physicians and other prescribers who treated elderly dementia patients by urging the prescribers to use Risperdal to treat symptoms such as anxiety, agitation, depression, hostility and confusion.

The Justice Department said the company created written sales aids for use by Janssens ElderCare sales force that emphasized symptoms and minimized any mention of the FDA-approved use, treatment of schizophrenia.

The company also provided incentives for off-label promotion and intended use by basing sales representatives bonuses on total sales of Risperdal in their sales areas, not just sales for FDA-approved uses, Justice Department officials said in the release.

When pharmaceutical companies interfere with the FDAs mission of ensuring that drugs are safe and effective for the American public, they undermine the doctor-patient relationship and put the health and safety of patients at risk, Director of the FDAs Office of Criminal Investigations John Roth said in the press release.

Todays settlement demonstrates the governments continued focus on pharmaceutical companies that put profits ahead of the publics health. The FDA will continue to devote resources to criminal investigations targeting pharmaceutical companies that disregard the drug approval process and recklessly promote drugs for uses that have not been proven to be safe and effective.

The charges in this case were filed under the Federal Food, Drug, and Cosmetic Act (FDCA), which protects the health and safety of the public by ensuring, among other things, that drugs intended for use in humans are safe and effective for their intended uses and that the labeling of such drugs bear true, complete and accurate information, said Resource4thePeople.

The federal officials outlined the following procedures in their press release:

Under the FDCA, a pharmaceutical company must specify the intended uses of a drug in its new drug application to the FDA. Before approval, the FDA must determine that the drug is safe and effective for those specified uses.

Once the drug is approved, if the company intends a different use and then introduces the drug into interstate commerce for that new, unapproved use, the drug becomes misbranded. The unapproved use is also known as an off-label use because it is not included in the drugs FDA-approved labeling.

SOURCES:

*http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html







More Bipolar Disorder Symptoms Press Releases

Comments Off

Filed under Bipolar Disorder Symptoms

Living with Bipolar Disorder

Living with Bipolar Disorder

Living with Bipolar Disorder.

A promising Princeton scholar of string theory, a gold-medal athlete, an artistic photographer, a husband and father, and a valued employee, Percy Paul was a…
Video Rating: 5 / 5

8 Comments

Filed under Bipolar Disorder

Six Months After the Affordable Care Act, Mental Health Treatment Still Not Accessible for Many Americans


Fort Lauderdale, Fla. (PRWEB) June 30, 2014

Six months ago, the Affordable Care Act (ACA) made behavioral health treatment one of 10 essential health care benefits, but so far few people are seeing the benefits. Fort Lauderdale based mental health treatment provider, the Sylvia Brafman Mental Health Center, believes this may be due to the stigma that follows mental health treatment.

Unfortunately, many people are still opposed to seeking mental health treatment, said Ben Brafman, a veteran of the behavioral health industry and founder of the Sylvia Brafman Mental Health Center. Stigma is still a factor, but so is uncertainty. People arent always sure that they need mental health treatment, nor do they know what to expect from treatment.

Historically, mental health treatment has been treated differently than physical health when it comes to insurance coverage. Mental health parity is a key element of the Affordable Care Act requiring insurers to provide coverage for behavioral health on par with what is provided for physical health. As of January 2014, many individuals received expanded behavioral health treatment coverage, however barriers to access are still preventing people from receiving treatment.

Although the ACA has made mental health treatment more affordable in some aspects, it is still not accessible for everyone, said Brafman, a 20-year behavioral health expert. This is particularly relevant for the people who fall between the cracks of getting insurance coverage at work and qualifying for Medicaid.

Some states have opted not to expand Medicaid to cover the gap between private insurance and Medicaid, making it difficult for those who come in between to access mental health treatment.

The Sylvia Brafman Mental Health Center provides treatment for a wide variety of behavioral health disorders through insurance or private pay. The stigma of mental health treatment prevents many clients from accessing their behavioral health benefits.

There are still many barriers for people seeking mental health treatment. Although parity laws help decrease the stigma of behavioral health, there is still a long way to go, said Brafman. We hope that in the next six months through education about the law, coverage and treatment programs that were able to expand access to mental health treatment for those in our community. “

####

The Sylvia Brafman Mental Health Center is a full service mental health facility located in Fort Lauderdale, Fla. Dedicated to helping individuals who suffer from mental illness find a path to living better, The Sylvia Brafman Mental Health Center offers a mental health program and support for a wide variety of mood and thought disorders including: depression, anxiety disorders, anger management, eating disorders, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and schizoaffective disorder. For more information on mental health treatment please contact The Sylvia Brafman Mental Health Center at 1-888-205-2775 or online at http://www.mentalhealthcenter.org.







More Bipolar Support Press Releases

Comments Off

Filed under Bipolar Support

'Speak Your Mind Texas' Campaign sparks discussion about help for mental

'Speak Your Mind Texas' Campaign sparks discussion about help for mental
“I cannot imagine that fight.” She said Kody suffers from a bipolar type of schizoeffective disorder and suspects he experienced sexual abuse and other emotional traumas. …. Three-quarters required treatment for alcohol abuse or drug dependency …
Read more on Midland Reporter-Telegram

Impact of depressive episodes on cognitive deficits in early bipolar disorder
A total of 68 patients and 38 controls from the Systematic Treatment Optimization Programme for Early Mania (STOP-EM) first-episode mania programme were examined. We conducted (a) a cross-sectional analysis of the impact of prior depressive episodes …
Read more on British Journal of Psychiatry

Rare gene could increase risk of schizophrenia, alcoholism and bipolar
Treatment for schizophrenia and bipolar disorder focuses on eliminating the symptoms of the conditions, as the specific causes are unknown. The new research could, however, lead to new treatments as a further clue to the genesis of such conditions is …
Read more on Medical News Today

Comments Off

Filed under Bipolar Mania Treatment

Healthy Living Institute – Self-Care and Coping With Bipolar Disorder and Depression


Healthy Living Institute – Self-Care and Coping With Bipolar Disorder and Depression

from Living With Bipolar Disorder and Manic Depression

Price: USD 0.99
View Details about Healthy Living Institute

Comments Off

Filed under Bipolar Depression

Latest Bipolar Disorder Symptoms News

Why people with bipolar disorder are bigger risk-takers
The study by the Universities of Manchester and Liverpool, published today [Wednesday 9 July] in the journal Brain, used brain imaging to identify neural pathways that are responsible for the symptoms of the disorder. The findings will help to design …
Read more on Medical Xpress

Mental-health App Can Predict Well-being
By passively analyzing mobile data, the app can detect if a patient with mental illness — such as depression, anxiety and bipolar disorders or schizophrenia — is acting symptomatic. Symptoms may include lethargy (decreased movement captured by motion …
Read more on Laboratory Equipment

Comments Off

Filed under Bipolar Disorder Symptoms

Research and Markets: Bipolar Disorder (Manic Depression) Global Clinical

Research and Markets: Bipolar Disorder (Manic Depression) Global Clinical
Our clinical trial report, Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2014" provides data on the Bipolar Disorder (Manic Depression) clinical trial scenario. This report provides elemental information and data relating to …
Read more on Business Wire (press release)

Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2014
[USPRwire, Wed Jul 02 2014] GlobalData's clinical trial report, "Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2014" provides data on the Bipolar Disorder (Manic Depression) clinical trial scenario. This report provides …
Read more on USPRwire (press release)

Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2014
FOR IMMEDIATE RELEASE, Illinois – United States – June 30,2014 (PR Carbon): Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2014 is a new market research publication announced by Reportstack. This report provides data on the …
Read more on PR Carbon (press release)

Comments Off

Filed under Bipolar Depression